ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.4600
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.4600
Open3.4300
Bid3.4200 x 4000
Ask3.4800 x 1200
Day's Range3.4100 - 3.4800
52 Week Range2.5300 - 3.9600
Volume464,670
Avg. Volume808,412
Market Cap564.194M
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.98
Trade prices are not sourced from all markets
  • Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?
    Simply Wall St.

    Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?

    The big shareholder groups in Antares Pharma, Inc. (NASDAQ:ATRS) have power over the company. Large companies usually...

  • GlobeNewswire

    Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • MarketWatch

    Teva says FDA-approved generic EpiPen is now available in the U.S. for $300 for a 2-pack

    Teva Pharmaceutical Industries Ltd. said Tuesday its FDA-approved generic version of the EpiPen is available in the U.S. at most retail pharmacies at a wholesale cost of $300 for a 2-pack. The news comes after a period of shortages for the EpiPen, a life-saving allergy treatment that is made by Mylan N.V. . The Teva generic uses Antares Pharma VIBEX(R) device. Antares and Teva have an exclusive license, development and supply Agreement for epinephrine auto injector products that Teva markets in the U.S. Teva shares rose 0.6% premarket, but have fallen 57% in 2019, while the S&P 500 has gained 17"%.

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Q2 2019 Antares Pharma Inc Earnings Call

  • Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript

    ATRS earnings call for the period ending June 30, 2019.

  • Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven
    Simply Wall St.

    Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven

    Antares Pharma, Inc.'s (NASDAQ:ATRS): Antares Pharma, Inc. focuses on developing and commercializing self-administered...

  • GlobeNewswire

    Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.0 to $110.0 Million.

  • GlobeNewswire

    Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

    Antares Pharma, Inc. (ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (HTGC), (“Hercules”), to increase the available debt capital by $25 million for a term loan of up to $50 million. At the same time Antares also provided notice of the termination of the At-The-Market (“ATM”) equity offering facility which will be effective on July 6, 2019.

  • Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)
    Insider Monkey

    Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)

    We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Antares Pharma Inc (NASDAQ:ATRS). Is Antares […]

  • GlobeNewswire

    Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 10:20 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?
    Simply Wall St.

    Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

    Antares Pharma, Inc. (ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday May 23, 2019 at 1:30 pm Pacific Daylight Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Antares Pharma Inc Earnings Call

  • Investors Who Bought Antares Pharma (NASDAQ:ATRS) Shares Three Years Ago Are Now Up 265%
    Simply Wall St.

    Investors Who Bought Antares Pharma (NASDAQ:ATRS) Shares Three Years Ago Are Now Up 265%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Antares Pharma Inc (ATRS) Q1 2019 Earnings Call Transcript
    Motley Fool

    Antares Pharma Inc (ATRS) Q1 2019 Earnings Call Transcript

    ATRS earnings call for the period ending March 31, 2019.

  • Associated Press

    Antares Pharma: 1Q Earnings Snapshot

    On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 3 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire

    Antares Pharma Reports First Quarter 2019 Operating and Financial Results

    EWING, N.J., May 02, 2019 -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019.  The.

  • GlobeNewswire

    Antares Pharma to Report First Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the market opens on Thursday, May 2, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on May 2, 2019 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-458-4121 or 1-323-794-2597 and entering access code 2251670.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Thursday, May 2, 2019, through 11:30 a.m. ET on Saturday, June 1, 2019 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 2251670.  An archive of the slide presentation will also be available under the “For Investors” section of the Antares Website at www.antarespharma.com.

  • Why Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Pay Matters To You
    Simply Wall St.

    Why Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Pay Matters To You

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Bob Apple has been the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) since 2016. This report will, first, examine the...

  • GlobeNewswire

    New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate

    Antares Pharma, Inc. (ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate (“MTX”) for the treatment of ectopic pregnancy that meets predefined criteria for medical management.  Antares plans to initiate a development program utilizing a proprietary auto injector device with doses of methotrexate not commercially approved or available in an auto injector in order to provide potential benefits for both patients and healthcare professionals.

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 28-Feb-19 1:30pm GMT

    Q4 2018 Antares Pharma Inc Earnings Call